FDA Explores Faster Track for Early Drug Testing
Published Date: 6/24/2026
Notice
Summary
The FDA wants to speed up how fast new drugs get tested on people by creating a special pilot program. This program will team up trusted research groups with drug makers to review early study plans faster, while keeping safety top priority. If you’re involved in drug research or healthcare, now’s your chance to share ideas before July 22, 2026!
Analyzed Economic Effects
3 provisions identified: 2 benefits, 1 costs, 0 mixed.
Faster First‑in‑Human Trials
FDA proposes a pilot to shorten the time from nonclinical research to first‑in‑human (FIH) studies by using qualified research institutions (QRIs), a rolling IND submission platform, and parallel activities like IRB review and site contracting. The pilot would allow FDA to review IND components on a rolling basis and could result in a "safe to proceed" notification before the 30‑day IND review period ends and fewer Phase 1 clinical holds.
Sponsors Pay QRIs Directly
The notice states that following the pilot, FDA expects sponsors will pay fees directly to Qualified Research Institutions (QRIs), and FDA will not set or collect those fees. Sponsors that participate should expect to pay QRIs for services after the pilot.
FDA Keeps Final Decision Authority
FDA will limit QRIs to advisory roles and will remain solely responsible for regulatory decisions. FDA retains authority to issue clinical holds, disqualify investigators, disqualify or restrict IRBs or institutions, require safety reporting, and conduct inspections.
Personalized for You
How does this regulation affect your finances?
Personalize government policy and PRIA will tell you what this federal register document means for your household, plus every other regulation we track. PRIA reads each provision against your financial profile to show you exactly what matters to your wallet.
Key Dates
Department and Agencies
Related Federal Register Documents
2026-14073, Drug Establishment Registration and Drug Listing Requirements for Establishments Engaged in Distributed Manufacturing and Certain Foreign Establishments
The FDA wants to make it easier for drug makers who work in several locations to register as one company instead of many. They’re also updating rules for foreign drug companies to match new laws about handling health threats. If you’re in drug manufacturing, get ready to comment by September 11, 2026, and keep an eye on possible paperwork changes that could affect your business.
2026-13047, Establishment Registration and Product Listing for Tobacco Products
The FDA wants to make sure all tobacco product makers, both in the U.S. and abroad, register their businesses and list their products. This new rule closes a big gap by including foreign companies, helping the FDA keep better track of tobacco products for public health. Comments on this proposal are open until September 14, 2026, so affected businesses should get ready to update their info and possibly face new costs.
2026-15920, Micro-Tracers, Inc.; Response to Objections and Requests for a Public Hearing
The Food and Drug Administration (FDA or we) received objections and requests for a public hearing submitted by Buchanan Ingersoll & Rooney PC, on behalf of Micro-Tracers, Inc. (Micro-Tracers or objector), on the order granting a color additive petition (3C0323) requesting that we repeal specified regulations to no longer provide for the safe use of FD&C Red No. 3 in food (including dietary supplements) and ingested drugs. After reviewing the objections, we have concluded that the objections do not raise issues of material fact that justify a hearing. We are also providing notice that the administrative stay of the effective date for the repeal and delisting of the color additive regulations is now lifted.
2026-15613, Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs; Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a final guidance for industry titled "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs." This guidance provides recommendations for the design and conduct of studies evaluating the adhesion performance of a transdermal or topical delivery system (collectively referred to as TDS). Depending on the objectives of a generic TDS product development program, applicants may choose to evaluate TDS adhesion in studies performed to evaluate TDS adhesion only, or in studies performed with a combined purpose (e.g., for the simultaneous evaluation of adhesion and bioequivalence (BE) with pharmacokinetic (PK) endpoints). The recommendations in this guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The guidance replaces the draft guidance (Revision 2) "Assessing Adhesion With Transdermal and Topical Delivery Systems for ANDAs," issued on April 13, 2023.
2026-15635, Angela Anatilde Baquero: Final Debarment Order
The Food and Drug Administration (FDA or the Agency) is issuing an order under the Federal Food, Drug, and Cosmetic Act (FD&C Act) permanently debarring Angela Anatilde Baquero from providing services in any capacity to a person that has an approved or pending drug product application. FDA bases this order on a finding that Angela Anatilde Baquero was convicted of a felony under Federal law for conduct relating to the development or approval, including the process for development or approval, of any drug product. Mrs. Baquero was given notice of the proposed debarment and an opportunity to request a hearing within the timeframe prescribed by regulation. As of May 6, 2026 (30 days after receipt of the notice), Mrs. Baquero has not responded. Mrs. Baquero's failure to respond and request a hearing constitutes a waiver of Mrs. Baquero's right to a hearing concerning this matter.
2026-15612, Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs; Revised Draft Guidance for Industry; Availability
The Food and Drug Administration (FDA or Agency) is announcing the availability of a revised draft guidance for industry titled "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs." This revised draft guidance provides recommendations for the design and conduct of studies to evaluate the in vivo skin irritation (and sensitization, if applicable) potential of a proposed transdermal or topical delivery system (collectively referred to as TDS). The recommendations in this revised draft guidance relate to studies submitted in support of an abbreviated new drug application (ANDA). The revised draft guidance is intended to clarify FDA's recommendations and expectations related to in vivo skin irritation and in vivo combined skin irritation and sensitization studies. This draft guidance replaces the draft guidance "Assessing the Irritation and Sensitization Potential of Transdermal and Topical Delivery Systems for ANDAs" (April 2023).
Previous / Next Documents
Previous: 2026-12620, Master Protocols for Drug and Biological Product Development; Draft Guidance for Industry; Availability
The FDA just dropped a fresh draft guidance to help drug and biological product makers run smarter, faster clinical trials using master protocols. This update affects companies developing new medicines by clarifying how to design and submit these trials for approval. If you’re in the game, get your comments in by August 24, 2026, or risk missing out on shaping the final rules—and maybe saving time and money down the road!
Next: 2026-12622, Demonstrating Substantial Evidence of Effectiveness for Human Drug and Biological Products; Revised Draft Guidance for Industry; Availability
The FDA just released a new draft guide to help drug makers prove their medicines really work, using smarter and faster science. This update affects companies developing human drugs and biological products, aiming to save time and money by allowing strong evidence from just one good clinical study plus extra proof. Comments on this draft are open until September 22, 2026, so industry folks have a chance to weigh in before it becomes final.